Finance

Lists
RVTY:NYSE
Revvity Inc
149,77 $
-0,83%
(-1,25) 1D
29 սեպ, 10:55:51 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RVTY...
Open
150,49 $
High
152,10 $
Low
149,29 $
Mkt. cap
16,85 մլրդ
Avg. vol.
1,97 մլն
Volume
171,22 հզր
52-wk high
152,26 $
52-wk low
81,22 $
Beta
1,09
Shares outstanding
111,59 մլն
No. of employees
11 հզր
Open
150,49 $
High
152,10 $
Low
149,29 $
Mkt. cap
16,85 մլրդ
Avg. vol.
1,97 մլն
Volume
171,22 հզր
52-wk high
152,26 $
52-wk low
81,22 $
Beta
1,09
Shares outstanding
111,59 մլն
No. of employees
11 հզր
News stories
From web sources and news partners
Profile
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY. Wikipedia
About Revvity Inc
CEOPrahlad Singh
Employees11 հզր
Founded1947
HeadquartersՈւոլթեմ, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 13 analysts giving stock ratings to RVTY in the past 3 months
Buy
Buy
4
Hold
9
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for RVTY in the last 3 months.
Highest
Current 149,77 $
165,00 $ (+10,17%)
Average
127,36 $ (-14,96%)
Lowest
110,00 $ (-26,55%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eve Burstein
Bernstein
Hold
Maintained
120,00 $
-19,9%
09/25/2026
Evie Koslosky
Goldman Sachs
Hold
Maintained
140,00 $
-6,5%
09/20/2026
Unknown Analyst
CFRA
Hold
Downgraded
-
-
09/18/2026
Unknown Analyst
UBS
Hold
Initiated
140,00 $
-6,5%
09/08/2026
Doug Schenkel
UBS
Hold
Downgraded
140,00 $
-6,5%
09/09/2026
Paul Knight
KeyBanc
Buy
Maintained
165,00 $
+10,2%
09/04/2026
Unknown Analyst
KeyBanc
Buy
Maintained
165,00 $
+10,2%
09/04/2026
Dan Leonard
RBC Capital
Hold
Initiated
135,00 $
-9,9%
09/01/2026
Casey Woodring
J.P. Morgan
Hold
Maintained
110,00 $
-26,6%
08/06/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
126,00 $
-15,9%
08/05/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
110,00 $
-26,6%
08/05/2026
Daniel Arias
Stifel Nicolaus
Hold
Reiterated
110,00 $
-26,6%
08/05/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
130,00 $
-13,2%
08/07/2026
Luke Sergott
Barclays
Hold
Maintained
115,00 $
-23,2%
08/04/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
07/17/2026
Michael Polark
Wolfe Research
Hold
Initiated
-
-
06/01/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
05/14/2026
Unknown Analyst
Guggenheim
Hold
Reiterated
-
-
05/11/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
117,00 $
-21,9%
05/04/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
95,00 $
-36,6%
04/14/2026
Jack Meehan
Nephron
Hold
Upgraded
90,00 $
-39,9%
03/26/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
110,00 $
-26,6%
02/03/2026
Tycho Peterson
Jefferies
Hold
Maintained
105,00 $
-29,9%
02/02/2026
Last report
04 օգս, 2026 թ.
Fiscal period
Q2 2026
EPS / Est. (USD)
1,41 $ / 1,22 $
+15,93%beat
Revenue / Est. (USD)
729,69 մլն / 702,97 մլն
+3,80%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. ապր
2026 թ. հլս
Revenue
698,95 մլն
772,06 մլն
711,12 մլն
729,69 մլն
Cost of goods sold
324,34 մլն
350,40 մլն
323,46 մլն
312,82 մլն
Cost of revenue
324,34 մլն
350,40 մլն
323,46 մլն
312,82 մլն
Research and development expenses
50,80 մլն
58,18 մլն
57,89 մլն
48,97 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
227,44 մլն
208,55 մլն
241,91 մլն
243,46 մլն
Operating expense
278,23 մլն
266,73 մլն
299,80 մլն
292,43 մլն
Total operating expenses
602,58 մլն
617,12 մլն
623,26 մլն
605,25 մլն
Operating income
96,37 մլն
154,93 մլն
87,86 մլն
124,44 մլն
Other non operating income
-
-
-
-
EBT including unusual items
55,68 մլն
91,56 մլն
49,99 մլն
63,53 մլն
EBT excluding unusual items
76,49 մլն
133,38 մլն
65,92 մլն
105,36 մլն
Income tax expense
8,46 մլն
-4,21 մլն
9,10 մլն
10,05 մլն
Effective tax rate
15,20%
-4,60%
18,20%
15,82%
Other operating expenses
-
-
-
-
Net income
46,65 մլն
98,36 մլն
40,72 մլն
51,82 մլն
Net profit margin
6,67%
12,74%
5,73%
7,10%
Earnings per share
1,18
1,70
1,06
1,41
Interest and investment income
6,92 մլն
5,75 մլն
6,30 մլն
5,26 մլն
Interest expense
-22,77 մլն
-23,51 մլն
-24,72 մլն
-22,99 մլն
Net interest expenses
-15,85 մլն
-17,76 մլն
-18,41 մլն
-17,73 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
198,43 մլն
258,01 մլն
192,91 մլն
226,47 մլն
Gain or loss from assets sale
-
-
-5,07 մլն
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps